Could a 5-Day pill shield frail seniors from COVID's worst outcomes?
NCT ID NCT07089680
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This study looks at whether the antiviral medication Paxlovid can reduce the risk of severe illness, death, and loss of daily functioning in older adults living in long-term care hospitals in Korea. Researchers will compare health outcomes of residents aged 60 and older who received Paxlovid for COVID-19 with those who did not, using medical records. The goal is to see if this treatment helps maintain independence and cognitive function in a vulnerable population.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nirmatrelvir and ritonavir (Paxlovid), an oral antiviral medication
- What this could lead to
- If effective, Paxlovid could help protect vulnerable older adults in long-term care from severe COVID-19, death, and loss of independence.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. The medication's benefits in this frail population are not yet confirmed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
937 people
The number who actually took part.
- Started
-
Sep 2025
- Finished
-
May 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population includes residents of long-term care hospitals (LTCHs) in Korea who are aged 60 years or older and were diagnosed with COVID-19 between January 14, 2022 and June 1, 2023 (or latest available date). Diagnosis was confirmed by SARS-CoV-2 PCR or antigen test, and symptom onset date was available. Participants were either treated with Paxlovid (Nirmatrelvir/Ritonavir) within 5 days of symptom onset or received no antiviral treatment. Patients were excluded if they received other COVID-19 treatments (e.g., remdesivir, molnupiravir, monoclonal antibodies), had severe renal or hepatic dysfunction, or had contraindicated medications. The study uses retrospective medical chart data and includes follow-up for up to 365 days.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* LTCH residents ≥60 years of age, diagnosed with COVID-19 via SARS-CoV-2 PCR or antigen test, with a symptom onset date (index date) between 14 January 2022 and 1 June 2023 (or latest date available) * Dispensed Paxlovid within 5 days of COVID-19 symptom onset (Paxlovid treated patients only)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronavirus disease 2019 (COVID-19) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gangnam-gu Haengbok Convalescence Hospital
Gangnam-gu, South Korea
-
Incheon Eun-Hye Convalescent Hospital
Seogu, South Korea
-
Jeonnam Jeil Hospital
Hwasun-gun, South Korea
-
Seocho-Cham Nursing Hospital
Seocho-gu, South Korea
-
Songdo Hyoja Hospital
Yeonsu-gu, South Korea
-
The Good Light Hospital
Gwangju, 12748, South Korea
-
bobath Memorial Hospital
Gyeonggi-do, 13552, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.